trending Market Intelligence /marketintelligence/en/news-insights/trending/yUlfawxlQfceSYTnONa7Gg2 content esgSubNav
In This List

Bristol-Myers selects 1st clinical candidate under collaboration with CytomX

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Bristol-Myers selects 1st clinical candidate under collaboration with CytomX

CytomX Therapeutics Inc. said Bristol-Myers Squibb Co. selected the first clinical candidate for its CTLA-4 Probody program under the strategic oncology collaboration established in May 2014.

This milestone achievement results in a $2 million payment to CytomX.

CTLA-4 is a clinically validated inhibitory immune checkpoint protein. It is the most advanced target from the companies' collaboration, which now also includes three additional, unnamed targets in discovery.